Snyder Mark Howard 4

What Happened
Mark Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics (HALO), received a package of equity awards on February 9, 2026 that totals 78,087 derivative shares. The filing shows five separate awards acquired at $0.00 (i.e., compensation grants, not market purchases): 18,730 (option-like award), 17,396 (time-based RSUs), 4,651 (PSUs tied to a 2023 grant), 7,808 (PSUs tied to a 2024 grant), and 29,502 (PSUs tied to a 2025 grant). These awards are subject to the vesting and performance/service conditions described below.

Key Details

• Transaction date: 2026-02-09; Form 4 filed 2026-02-11 (timely within the typical two-business-day window).
• Total awarded: 78,087 derivative shares; acquisition price reported as $0.00 (compensation grants).
• Breakdown and vesting notes:
  • 18,730 — option-style award (F1): vests 1/4 on a specified date, then 1/48th monthly thereafter.
  • 17,396 — time-based RSUs (F2): vests 1/4 on first anniversary, then 1/4 on each subsequent anniversary.
  • 4,651 — performance stock units from 2/16/2023 (F3): performance determination made for period ending 12/31/2025; units remain subject to service vesting through the 3rd anniversary of the grant date.
  • 7,808 — performance stock units from 2/23/2024 (F4): performance determination made for period ending 12/31/2025; units remain subject to service vesting through the 3rd anniversary of the grant date.
  • 29,502 — performance stock units from 2/20/2025 (F5): performance determination made for period ending 12/31/2025; units remain subject to service vesting through the 3rd anniversary of the grant date.
• Shares owned after the transaction: not specified in the provided filing.
• No sale, open-market purchase, cashless exercise, tax withholding, or 10b5-1 plan is indicated in the reported transactions.

Context
These are compensation grants and/or performance-based units rather than open-market purchases or sales — they do not represent an immediate cash outflow or market transaction. Performance stock units (PSUs) listed were adjusted/credited based on performance measurement periods ending Dec 31, 2025 but still require continued service (and in some cases additional vesting conditions) before resulting in issued common shares. For retail investors: awards show how the company compensates executives but are not a direct bullish/bearish signal like an insider buy or sell in the market.